A detailed history of Hartford Investment Management CO transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Hartford Investment Management CO holds 127,447 shares of BMY stock, worth $7.35 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares
127,447
Previous 129,676 1.72%
Holding current value
$7.35 Million
Previous $5.39 Million 22.47%
% of portfolio
0.22%
Previous 0.19%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 22, 2024

SELL
$39.66 - $51.75 $88,402 - $115,350
-2,229 Reduced 1.72%
127,447 $6.6 Million
Q2 2024

Aug 01, 2024

SELL
$40.25 - $52.99 $70,477 - $92,785
-1,751 Reduced 1.33%
129,676 $5.39 Million
Q1 2024

Apr 17, 2024

SELL
$47.98 - $54.4 $265,473 - $300,995
-5,533 Reduced 4.04%
131,427 $7.13 Million
Q4 2023

Jan 23, 2024

SELL
$48.48 - $57.85 $322,925 - $385,338
-6,661 Reduced 4.64%
136,960 $7.03 Million
Q3 2023

Oct 16, 2023

SELL
$57.89 - $64.73 $284,529 - $318,147
-4,915 Reduced 3.31%
143,621 $8.34 Million
Q2 2023

Jul 19, 2023

SELL
$63.71 - $70.74 $2.02 Million - $2.24 Million
-31,708 Reduced 17.59%
148,536 $9.5 Million
Q1 2023

May 09, 2023

BUY
$65.71 - $74.53 $1.68 Million - $1.9 Million
25,547 Added 16.51%
180,244 $12.5 Million
Q4 2022

Jan 20, 2023

SELL
$68.48 - $81.09 $4.27 Million - $5.05 Million
-62,326 Reduced 28.72%
154,697 $11.1 Million
Q3 2022

Nov 02, 2022

BUY
$0.13 - $76.84 $209 - $124,096
1,615 Added 0.75%
217,023 $15.4 Million
Q2 2022

Jul 22, 2022

SELL
$72.62 - $79.98 $152,284 - $167,718
-2,097 Reduced 0.96%
215,408 $16.6 Million
Q1 2022

Apr 20, 2022

SELL
$61.48 - $73.72 $1.18 Million - $1.42 Million
-19,211 Reduced 8.12%
217,505 $15.9 Million
Q4 2021

Feb 02, 2022

BUY
$53.63 - $62.52 $963,087 - $1.12 Million
17,958 Added 8.21%
236,716 $14.8 Million
Q3 2021

Nov 01, 2021

SELL
$59.17 - $69.31 $2.06 Million - $2.41 Million
-34,829 Reduced 13.73%
218,758 $12.9 Million
Q2 2021

Jul 29, 2021

SELL
$61.91 - $67.42 $269,184 - $293,142
-4,348 Reduced 1.69%
253,587 $16.9 Million
Q1 2021

Apr 21, 2021

SELL
$59.34 - $66.74 $570,791 - $641,972
-9,619 Reduced 3.6%
257,935 $16.3 Million
Q4 2020

Feb 01, 2021

BUY
$57.74 - $65.43 $1.68 Million - $1.91 Million
29,133 Added 12.22%
267,554 $16.6 Million
Q3 2020

Oct 29, 2020

SELL
$57.43 - $63.64 $563,732 - $624,690
-9,816 Reduced 3.95%
238,421 $14.4 Million
Q2 2020

Aug 04, 2020

SELL
$54.82 - $64.09 $2.5 Million - $2.92 Million
-45,547 Reduced 15.5%
248,237 $14.6 Million
Q1 2020

Apr 24, 2020

BUY
$46.4 - $67.43 $1.05 Million - $1.53 Million
22,704 Added 8.38%
293,784 $16.4 Million
Q4 2019

Jan 29, 2020

BUY
$49.21 - $64.19 $3.47 Million - $4.53 Million
70,606 Added 35.22%
271,080 $17.4 Million
Q3 2019

Oct 28, 2019

SELL
$42.77 - $50.71 $769,090 - $911,867
-17,982 Reduced 8.23%
200,474 $10.2 Million
Q2 2019

Jul 25, 2019

BUY
$44.62 - $49.34 $92,140 - $101,887
2,065 Added 0.95%
218,456 $9.91 Million
Q1 2019

Apr 29, 2019

BUY
$45.12 - $53.8 $463,923 - $553,171
10,282 Added 4.99%
216,391 $10.3 Million
Q4 2018

Feb 04, 2019

BUY
$48.76 - $63.23 $127,361 - $165,156
2,612 Added 1.28%
206,109 $10.7 Million
Q3 2018

Nov 08, 2018

SELL
$55.19 - $62.25 $589,705 - $665,141
-10,685 Reduced 4.99%
203,497 $12.6 Million
Q2 2018

Jul 19, 2018

SELL
$50.53 - $62.98 $5.11 Million - $6.37 Million
-101,206 Reduced 32.09%
214,182 $11.9 Million
Q1 2018

Apr 24, 2018

SELL
$59.92 - $68.98 $1.36 Million - $1.57 Million
-22,709 Reduced 6.72%
315,388 $19.9 Million
Q4 2017

Feb 12, 2018

SELL
$59.94 - $65.35 $1.44 Million - $1.57 Million
-24,092 Reduced 6.65%
338,097 $20.7 Million
Q3 2017

Nov 13, 2017

BUY
$55.23 - $63.74 $20 Million - $23.1 Million
362,189
362,189 $23.1 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Hartford Investment Management CO Portfolio

Follow Hartford Investment Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hartford Investment Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Hartford Investment Management CO with notifications on news.